Natco Pharma’s generic Semaglutide set for roll out today
The Hindu
Natco Pharma will launch its Semaglutide injection (multi dose vials) in the domestic market on Saturday.
Natco Pharma will launch its Semaglutide injection (multi dose vials) in the domestic market on Saturday.
It will be available tomorrow, day 1 of patent expiry, the Hyderabad-based generic drugmaker said on Friday. Semaglutide is the active ingredient in drug major Novo Nordisk’s Ozempic and Wegovy. It is indicated for treatment of adults with type 2 diabetes as an adjunct to diet and exercise.
Last month, Natco had received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in multi dose vials and pen device based on the clinical comparison study.
Semaglutide injection will be launched in multi dose vials of different strengths under brand names Semanat and Semanfull. The MRP of the vials will be ₹1,290 per month for 2 mg/1.5ml and 4mg/3ml; and ₹1,750 for 8mg/3ml.
The product in pen device is expected to be launched in April, in the price band of ₹4,000-4,500 per month. Natco said it is the first company to offer generic Semaglutide in multi dose vials with customised syringes. It is also offering the product to third parties for co-marketing.
Separately, Eris Lifesciences, which last month had announced a partnership with Natco for commercialisation of Semaglutide in the country, said it will launch the product under Sundae brand. A GLP-1 receptor agonist, Semaglutide has emerged as a transformative therapy for Type 2 diabetes and weight management, driven by strong outcomes in glycemic control and weight reduction, it said.
Crude oil futures rise amid Middle East attacks, pushing Brent above $116 on fears of tightening global supply.
West Asia conflict delays India’s FTA talks with GCC and Israel, while UK and EU agreements proceed as planned in 2024.
Russian Urals oil vessels will reach India on March 21 amid stable fuel prices and diversified LPG imports.
Warner Bros. dominated the Academy Awards, but Paramount’s looming acquisition of the studio signals the biggest restructuring of the industry in decades and a battle over the future of Hollywood itself
HDFC Bank board calls Atanu Chakraborty’s resignation baffling, affirms robust corporate governance and strong market confidence.
RNFI and Jio Payments Bank launch cardless UPI QR cash withdrawals for instant access across urban, semi-urban, and rural India.
RBI approves HDFC Bank's chairman transition plan, affirming the bank's strong financials and competent management.
Markets fall 2% as Israel attacks Iran’s South Pars gas field, pushing Brent crude above $112 and rupee below ₹93.
HDFC Bank shares drop over 4% following chairman’s ethical resignation, raising insider trading and management concerns.
Erran Berger, the Vice President of Product Engineering at LinkedIn, thinks the former type of division of labour is rapidly disappearing
India mandates oil and gas firms to share import and export data to mitigate consumer shortages amid rising global prices.
HDFC Bank's chairman Atanu Chakraborty resigns over ethical concerns; Keki Mistry appointed interim chairman for three months.
Stock markets continue to rise for the third day as Sensex and Nifty gain nearly 1%, fueled by IT stocks.